HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has launched a pioneering initiative to broaden insurance coverage for critical treatments, promising a new era of accessibility in dermatologic care.
STRATA’s mission, designed to offer support for conditions such as mycosis fungoides, lichen planus, alopecia areata, and cutaneous T-Cell lymphoma (CTCL), initially zeroes in on vitiligo and atopic dermatitis. The two skin diseases affect up to 3 and 16 million individuals in the United States.
However, this initiative is not just about insurance coverage. It’s about enhancing patient quality of life and ensuring access to essential dermatologic treatments, as stated by Dr. Dolev Rafaeli, Vice Chairman and Chief Executive Officer of STRATA. “We’re advocating for the enhancement of patient quality of life and ensuring access to essential dermatologic treatments,” Dr. Rafaeli said.
STRATA’s irrepressible drive is seen in their strategy. The company is leveraging its extensive patient database, engaging in targeted governmental relations efforts and broadening Current Procedural Terminology (“CPT”) code coverage to better patient access while enabling higher provider reimbursement rates.
The company’s approach is looking promising. Initial outreach to a segment of its patient database has yielded encouraging results. The data is being utilized to engage with elected officials, amplifying patients’ voices and their needs.
STRATA’s initiative builds on the momentum of recent achievements in the healthcare industry that re-evaluated the CPT codes. The company has its sights set on expanding the coverage of phototherapy treatments under codes 96920, 96921, and 96922. These codes are specifically dedicated to excimer laser procedures for small, medium, and larger affected skin areas.
By deploying a comprehensive direct-to-consumer outreach initiative, STRATA hopes to magnify its initial outreach efforts, reaching its vast network of over 270,000 patients to enhance access to essential treatments.
The importance of this initiative shouldn’t be understated. Over the past two months, STRATA has dispatched over 1,000 legislative support letters to congressional and senate delegates advocating for its patients. Dr. Elisabeth G. Richard, Treasurer and Board of Directors of the Photodermatology Society and Assistant Professor of Dermatology at Johns Hopkins University School of Medicine, underlined the significance of this initiative, specifically the pivotal role of phototherapy for vitiligo sufferers.
STRATA is not alone in this fight. The company is actively engaging with multiple prominent patient advocacy societies and the broader dermatology community to enhance patient access to XTRAC treatments.
Through its vigorous advocacy work, STRATA Skin Sciences is playing a pivotal role in reshaping the landscape of dermatologic care, ensuring that essential treatments are not only highly effective but also accessible to those who need them the most.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.